STAAR Surgical Company - 10-Q Summary
Business Context and Reporting Period
Company: STAAR Surgical Company (STAAR)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: April 1, 2011
Business Overview: STAAR designs, develops, manufactures, and sells implantable lenses for the eye, specifically Intraocular Lenses (IOLs) for cataract surgery and Implantable Collamer Lenses (ICLs) for refractive surgery. The company operates as a single segment with significant international exposure (76% of sales outside the U.S.).
Key Financial Metrics
| Metric (in thousands) | Q1 2011 | Q1 2010 |
|---|---|---|
| Net Sales | $14,849 | $13,778 |
| Gross Profit | $9,629 | $8,829 |
| Gross Margin | 64.8% | 64.1% |
| Operating Income | $208 | $76 |
| Net Income | $300 | $3,530 |
| Net Income from Continuing Ops | $300 | $(636) |
| Cash and Cash Equivalents | $10,212 | $16,274 |
| Line of Credit Outstanding | $2,420 | $2,460 |
Note: Q1 2010 Net Income included $4.166 million from discontinued operations (sale of Domilens subsidiary). Q1 2011 Net Income represents the first quarter of profitability from continuing operations since 1999.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 7.8% year-over-year, driven by a 10.1% increase in core product sales (IOLs and ICLs). Currency fluctuations provided a $0.5 million favorable impact.
- Product Mix: ICL sales grew 17.6% to $6.9 million, while IOL sales grew 3.7% to $7.1 million. The shift toward higher-margin ICLs contributed to an improved gross margin.
- Profitability: Operating income increased from $76,000 to $208,000. The company achieved net income from continuing operations ($300,000), reversing a loss of $636,000 in the prior year period.
- Expenses: Marketing and selling expenses rose 16.5% due to the timing of the ASCRS trade show. Research and development expenses decreased 6.7% due to lower costs in Japan.
- Cash Flow: Net cash provided by operating activities turned positive at $550,000, compared to a use of $1.4 million in the prior year, largely due to improved net income and working capital management.
Guidance, Outlook, and Risks
Management Commentary & Strategy:
- 2011 Goals: Management targets double-digit total revenue growth, 25% growth in Visian ICL/TICL sales, a gross margin of 66% by year-end, and profitability in at least three of four quarters.
- Product Pipeline: Received CE Mark approval for the V4c Visian ICL (simplifies procedure) and nanoFLEX IOL. Seeking FDA approval for the Toric ICL (TICL) in the U.S. and Japan.
- Market Dynamics: U.S. ICL sales declined 7% due to a 60% drop in military sales, though private sector sales grew 12%. International growth remains strong in China, Japan, Germany, and India.
Risks and Contingencies:
- Japan Earthquake: The March 11, 2011 earthquake and tsunami caused minor facility damage but operations resumed quickly. Risks include supply chain interruptions, power blackouts, and potential consumer hesitation regarding elective procedures.
- Regulatory: FDA approval for the TICL remains pending; delays could impact growth in the U.S. refractive market.
- Executive Severance: Approximately $400,000 remains accrued for executive termination benefits to be paid over 15 months.
Investor Verification Checklist
- Sustainability of Profitability: Verify if Q1 2011 profitability from continuing operations is a trend or an anomaly, given the company's history of losses.
- U.S. Military Sales: Confirm the status of military contracts and the likelihood of recovery in this segment.
- Japan Operations: Monitor the long-term impact of the earthquake on supply chains and consumer demand for elective refractive surgery in Japan.
- Regulatory Approvals: Track the timeline for FDA approval of the Toric ICL (TICL), a key growth driver.
- Cash Position: Assess the adequacy of the $10.2 million cash balance against working capital needs and the $2.4 million line of credit utilization.